Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Investigation of metabolism and disposition of GSK1322322, a peptidase deformylase inhibitor, in healthy humans using the entero-test for biliary sampling.

Mamaril-Fishman D, Zhu J, Lin M, Felgate C, Jones L, Stump P, Pierre E, Bowen C, Naderer O, Dumont E, Patel P, Gorycki PD, Wen B, Chen L, Deng Y.

Drug Metab Dispos. 2014 Aug;42(8):1314-25. doi: 10.1124/dmd.114.058420. Epub 2014 May 28.

PMID:
24872378
2.

Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.

Bershas DA, Ouellet D, Mamaril-Fishman DB, Nebot N, Carson SW, Blackman SC, Morrison RA, Adams JL, Jurusik KE, Knecht DM, Gorycki PD, Richards-Peterson LE.

Drug Metab Dispos. 2013 Dec;41(12):2215-24. doi: 10.1124/dmd.113.053785. Epub 2013 Oct 4.

PMID:
24097902
3.

Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.

Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY.

Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16.

PMID:
23548165
4.

Investigations of hydrazine cleavage of eltrombopag in humans.

Deng Y, Rogers M, Sychterz C, Talley K, Qian Y, Bershas D, Ho M, Shi W, Chen EP, Serabjit-Singh C, Gorycki PD.

Drug Metab Dispos. 2011 Sep;39(9):1747-54. doi: 10.1124/dmd.111.040188. Epub 2011 Jun 6.

PMID:
21646438
5.

Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects.

Deng Y, Madatian A, Wire MB, Bowen C, Park JW, Williams D, Peng B, Schubert E, Gorycki F, Levy M, Gorycki PD.

Drug Metab Dispos. 2011 Sep;39(9):1734-46. doi: 10.1124/dmd.111.040170. Epub 2011 Jun 6.

PMID:
21646437
6.

Metabolism of [(14)C]GSK977779 in rats and its implication with the observed covalent binding.

Tsalta CD, Madatian A, Schubert EM, Xia F, Hardesty WM, Deng Y, Seymour JL, Gorycki PD.

Drug Metab Dispos. 2011 Sep;39(9):1620-32. doi: 10.1124/dmd.110.036467. Epub 2011 May 31.

PMID:
21628498
7.

Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.

McCleland BW, Davis RS, Palovich MR, Widdowson KL, Werner ML, Burman M, Foley JJ, Schmidt DB, Sarau HM, Rogers M, Salyers KL, Gorycki PD, Roethke TJ, Stelman GJ, Azzarano LM, Ward KW, Busch-Petersen J.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7. Epub 2006 Dec 23.

PMID:
17236763
8.

An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey.

Marquis RW, Ward KW, Roethke T, Smith BR, Ru Y, Yamashita DS, Tomaszek TA, Gorycki PD, Cheng HY, James IE, Stroup GB, Lark MW, Gowen M, Veber DF.

Mol Pharm. 2004 Jan 12;1(1):97-100. No abstract available.

PMID:
15832505
9.

Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.

Jin Q, Nie H, McCleland BW, Widdowson KL, Palovich MR, Elliott JD, Goodman RM, Burman M, Sarau HM, Ward KW, Nord M, Orr BM, Gorycki PD, Busch-Petersen J.

Bioorg Med Chem Lett. 2004 Sep 6;14(17):4375-8.

PMID:
15357956
10.

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: in vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man.

Ward KW, Proksch JW, Gorycki PD, Yu CP, Ho MY, Bush BD, Levy MA, Smith BR.

Xenobiotica. 2002 Mar;32(3):235-50.

PMID:
11958562
11.

Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel.

Li AP, Gorycki PD, Hengstler JG, Kedderis GL, Koebe HG, Rahmani R, de Sousas G, Silva JM, Skett P.

Chem Biol Interact. 1999 Jun 1;121(1):117-23. Review.

PMID:
10418974
12.

Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

Adams JL, Boehm JC, Kassis S, Gorycki PD, Webb EF, Hall R, Sorenson M, Lee JC, Ayrton A, Griswold DE, Gallagher TF.

Bioorg Med Chem Lett. 1998 Nov 17;8(22):3111-6.

PMID:
9873686
13.

Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.

Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttmann MA, Hay DW, Gorycki PD, Christensen SB, Torphy TJ.

J Pharmacol Exp Ther. 1998 Dec;287(3):988-95.

PMID:
9864284
14.

SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ.

J Pharmacol Exp Ther. 1998 Nov;287(2):705-11.

PMID:
9808700
15.

The oxidation of tetrasubstituted alkenes by cytochrome P450.

Gorycki PD, Macdonald TL.

Chem Res Toxicol. 1994 Nov-Dec;7(6):745-51.

PMID:
7696528
16.

The mechanism of aphidicolin bioinactivation by rat liver in vitro systems.

Edelson RE, Gorycki PD, MacDonald TL.

Xenobiotica. 1990 Mar;20(3):273-87.

PMID:
2110702
17.

Structure-activity relationships for the inhibition of DNA polymerase alpha by aphidicolin derivatives.

Prasad G, Edelson RA, Gorycki PD, Macdonald TL.

Nucleic Acids Res. 1989 Aug 11;17(15):6339-48.

Supplemental Content

Loading ...
Support Center